Institutional Investors Are Loading Up on Madrigal Pharmaceuticals Stock. Should You?
Madrigal has a first-mover advantage in treating MASH, a type of fatty liver disease.
Overview
The first commercial drug from Madrigal Pharmaceuticals (NASDAQ: MDGL) made a big splash in 2024 when the Food and Drug Administration (FDA) approved Madrigal's Rezdiffra as the first drug in the U.S. to treat metabolic dysfunction-associated steatohepatitis (MASH), a severe form of fatty liver disease.
The pharmaceutical stock is down more than 7% this year, but institutional investors are still high on the company. Baker Brothers Advisors owns 2.14 million shares, while the Janus Henderson Group owns 2.1 million, and RTW Investments owns 1.99 million shares of Madrigal. Institutional investors hold more than 95% of the company's float.
Details
Is there something those investors are seeing that retail investors are missing? Let's find out.
Source
Originally published at www.fool.com.